All articles by Staff Writer
Staff Writer
Cytovale’s FDA-Cleared Sepsis Diagnostic Triages First 5,000 Patients, Paves Way to New Hospital Protocols for Sepsis Management
First hospital to implement Cytovale’s IntelliSep® sepsis diagnostic tool realizes significant clinical and financial returns in first nine months of screening
Echo Hospice Receives Prestigious Center of Excellence Award from The Wound Pros
Leader in compassionate care honored for excellence in wound healing and dedication to community
Healcisio Receives Phase II STTR Funding to Continue Critical Care AI Research
Healcisio, a leader in AI and digital healthcare, announces it has received a $1 Million STTR Phase II award from the NIAID to advance the development of its critical care decision support platform and a new AI-powered software suite for abstracting and reporting quality measures.
Noul Participates in a Malaria Project Initiated by U.S. CDC with Kenya Medical Research Institute
On-Device AI healthcare company, Noul, announced that it will jointly participate in a malaria diagnosis project initiated by U.S. Centers for Disease Control and Prevention (CDC) with the Kenya Medical Research Institute (KEMRI).
Bio-Rad Extends Range of Anti-Biotherapeutic Antibodies to Accelerate Antibody Drug Development
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today launched four new anti-idiotypic antibodies to the following drugs: atezolizumab (Lemtrada), avelumab (Bavencio), obinutuzumab (Gazyvaro), and ocrelizumab (Ocrevus), extending its range of anti-biotherapeutic antibodies. The company also introduced its anti-monomethyl auristatin E (MMAE) biotherapeutic antibody range for bioanalysis.
Microbix Hosts Minister Nina Tangri to Open Capacity Expansions
Adds Product Development & QC Labs, Fully-Automated IVD Vial-Filling Capability
QIAGEN launches new QIAcuity digital PCR assays for microbial applications
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of 35 new wet-lab tested digital PCR Microbial DNA Detection Assays for its digital PCR (dPCR) platform QIAcuity, significantly enhancing its offerings in the field of microbial research. The new assays are available on QIAGEN’s comprehensive research platform GeneGlobe and are designed to target a wide range of pathogens responsible for tropical diseases, sexually transmitted infections (STIs) and urinary tract infections (UTIs), further solidifying QIAGEN’s position as a leader in microbial detection and analysis.
Nobel Laureate Professor Sir Martin Evans opens Molecular Devices’ Cardiff facility to manufacture patient-derived organoids for research and drug discovery
Molecular Devices is the world’s only company offering a service to manufacture standardized, quality-tested patient-derived organoids at a scale of many millions per batch
FIND and WHO sign new MoU to speed up innovation and access to quality diagnostics
FIND and the World Health Organization (WHO) have signed a new Memorandum of Understanding (MoU) that lays the foundation for accelerating innovation and achieving equitable accesss to quality diagnostics for people globally.
QIAGEN launches digital PCR Assay Design Tool for QIAcuity, expands customization capabilities of its research platform GeneGlobe
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its new digital PCR (dPCR) Custom Assay Design Tool for copy number variation (CNV) analysis for use on its digital PCR platform QIAcuity and several other enhancements in its GeneGlobe Design and Analysis Hub, a comprehensive research platform that integrates pre-designed assays with a database of more than 10,000 biological entities including genes, miRNAs, and pathways. The new advancements aim to support customers with a wide range of assay customization options, from simple to complex and validated multiplex assays, while further improving the user experience.